Aradigm Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
21,564.00
4,652.00
17,209.00
32,938.00
10,705.00
Depreciation, Depletion & Amortization
370.00
310.00
203.00
121.00
118.00
Other Funds
16,487.00
8,229.00
1,029.00
3,344.00
4,406.00
Funds from Operations
4,707.00
3,267.00
15,977.00
29,473.00
6,181.00
Changes in Working Capital
4,971.00
3,624.00
976.00
993.00
10,317.00
Net Operating Cash Flow
264.00
357.00
16,953.00
28,480.00
16,498.00
Capital Expenditures
43.00
412.00
-
75.00
154.00
Purchase/Sale of Investments
174.00
-
-
1,006.00
-
Net Investing Cash Flow
131.00
412.00
-
1,081.00
154.00
Issuance/Reduction of Debt, Net
-
-
-
20,586.00
-
Net Financing Cash Flow
40,322.00
164.00
175.00
20,690.00
150.00
Net Change in Cash
40,717.00
109.00
16,778.00
8,871.00
16,502.00
Free Cash Flow
221.00
55.00
16,953.00
28,555.00
16,652.00
Change in Capital Stock
40,322.00
164.00
175.00
104.00
150.00

About Aradigm

View Profile
Address
3929 Point Eden Way
Hayward California 94545
United States
Employees -
Website http://www.aradigm.com
Updated 09/14/2018
Aradigm Corp. operates as a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. Its technologies include diabetes and pain management, AERx essence devices. The company was founded in 1991 and is headquartered in Hayward, CA.